Invectys
Developing innovative approaches to immunotherapy to treat cancer.
Launch date
Employees
Market cap
-
Enterprise valuation
AUD102—153m (Dealroom.co estimates Oct 2018.)
Company register number 521505065
Paris Île-de-France (HQ)
Financials
Estimates*
| EUR | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | - | - | - | <1m | 2.4m | 1.3m | 1.3m |
| % growth | - | - | - | - | 277 % | (46 %) | - |
| EBITDA | (6.3m) | (6.6m) | (8.1m) | (5.9m) | (1.7m) | (3.9m) | - |
| % EBITDA margin | - | - | - | (937 %) | (72 %) | (302 %) | - |
| Profit | (4.9m) | (5.6m) | (6.7m) | (4.5m) | (1.2m) | (3.3m) | - |
| % profit margin | - | - | - | (713 %) | (51 %) | (254 %) | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
* | N/A | Spinout | |
| N/A | €1.5m | Seed | |
| N/A | €10.0m | Early VC | |
| N/A | €7.0m | Series A | |
* | N/A | €4.0m | Early VC |
| N/A | €15.0m | Early VC | |
| N/A | $14.2m | Grant | |
| Total Funding | AUD85.7m | ||
Related Content
Recent News about Invectys
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.